Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-Neo: Genotype-Matched Neoadjuvant Therapy in Advanced Thyroid Carcinoma
NCT07010393Phase 4Not yet recruiting
- Sponsor
- Fujian Medical University
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 4 trial of dabrafenib + trametinib, trametinib, selpercatinib, pralsetinib, larotrectinib in thyroid carcinoma (TC), sponsored by Fujian Medical University. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
dabrafenib + trametinibtrametinibselpercatinibpralsetiniblarotrectinib
03
Conditions
thyroid carcinoma (TC)
Beyond the preview
Go deeper on NCT07010393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07010393.